Related Experiment Video
Updated: Jul 18, 2026

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
Published on: November 25, 2025
Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression
Tatsui Otsuka1, Takashi Togo, Naoya Sugiyama
1Department of Psychiatry, Yokohama City University School of Medicine: 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
Abstract:
Obsessive-compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT(2A) and dopamine D(2) receptors, as well as a unique agonist effects on serotonin 5-HT(1A) receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Panic Disorder
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
